Workflow
昭衍新药(603127) - 2021 Q1 - 季度财报
603127JOINN(603127)2021-04-29 16:00

Financial Performance - Net profit attributable to shareholders was RMB 93.36 million, up 388.07% year-on-year[4] - Operating revenue for the period was RMB 200.99 million, representing a growth of 29.91% compared to the same period last year[4] - Basic earnings per share rose to RMB 0.39, a 333.33% increase from RMB 0.09 in the previous year[4] - Excluding the impact of foreign exchange gains, net profit growth rate was 85.44%[4] - The company reported a total comprehensive income of ¥62,388,926.44 for Q1 2021, compared to ¥22,630,107.43 in Q1 2020[23] - The company's net profit for Q1 2021 was CNY 56,060,823.09, a significant increase compared to CNY 934,455.09 in Q1 2020, reflecting a growth of approximately 5,900%[25] - Total revenue from operating activities reached CNY 334,525,902.11, up from CNY 232,670,305.50 in the same period last year, indicating a growth of about 43.8%[27] Assets and Liabilities - Total assets reached RMB 7.63 billion, an increase of 262.17% compared to the end of the previous year[4] - Total liabilities increased to ¥1,037,666,885.26, up from ¥883,657,479.78, representing a growth of approximately 17.5% year-over-year[16] - Current liabilities totaled ¥875,120,280.13, compared to ¥760,042,162.51, indicating an increase of about 15.1%[16] - Non-current liabilities rose to ¥162,546,605.13 from ¥123,615,317.27, reflecting a growth of approximately 31.5%[16] - Total equity attributable to shareholders reached ¥6,597,313,422.62, significantly up from ¥1,224,899,092.29, marking an increase of around 438.5%[17] - Total assets of the company reached ¥7,633,988,121.93, a substantial increase from ¥2,107,821,636.06, reflecting overall growth in the company's financial position[15] - Total liabilities amounted to ¥883,657,479.78, a decrease of ¥67,435,620.28 compared to the previous period[33] Cash Flow - The company reported a net cash flow from operating activities of RMB 34.48 million, a slight increase of 0.49% year-on-year[4] - Cash and cash equivalents increased significantly to ¥5,657,723,895.31 from ¥308,689,959.55, a change of 1732.82% due to funds raised from the Hong Kong stock market[9] - The net cash flow from financing activities was ¥5,312,443,354.88, a dramatic increase of 331480.4% compared to ¥1,602,158.28 in the previous period, mainly due to funds raised from the Hong Kong stock market[12] - Cash inflow from operating activities totaled CNY 127,310,706.37, a significant increase of 86% compared to CNY 68,375,500.49 in Q1 2020[30] - The net increase in cash and cash equivalents was CNY 5,365,357,040.52, compared to a decrease of CNY 6,288,742.53 in the previous year[31] Shareholder Information - The number of shareholders reached 21,198 by the end of the reporting period[7] - The top shareholder, Feng Yuxia, holds 23.66% of the shares, totaling 64,073,468 shares[8] Other Financial Metrics - The weighted average return on equity increased by 0.80 percentage points to 3.08%[4] - The company completed its H-share listing on February 26, 2021, raising HKD 6.373 billion, with a foreign exchange gain impacting net profit by RMB 57.89 million[4] - The company incurred financial expenses of CNY 67,971,575.70, compared to CNY 45,241.27 in the previous year, indicating a rise in financial costs[25] - Research and development expenses for Q1 2021 were ¥9,878,808.23, a decrease of 16% from ¥11,760,553.48 in Q1 2020[22]